Evidence from both papillary thyroid carcinoma and triple-negative breast cancer suggests that elevated CXCL10 expression consistently correlates with improved prognosis, likely reflecting its role in promoting antitumor immune responses across distinct tumor types (42, 43). Here, CXCL10 is linked to triple-negative breast carcinoma.